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Abstract
Background and purpose: Cerebellar ataxia with sensory ganglionopathy (SG) is a disabling combination of
neurological dysfunction usually seen as part of some hereditary ataxias. However, patients may present with this
combination without a genetic cause.
Methods: We reviewed records of all patients that have been referred to the Sheffield Ataxia Centre who
had neurophysiological and imaging data suggestive of SG and cerebellar ataxia respectively. We excluded
patients with Friedreich’s ataxia, a common cause of this combination. All patients were screened for genetic
causes and underwent extensive investigations.
Results: We identified 40 patients (45% males, mean age at symptom onset 53.7 ± 14.7 years) with combined
cerebellar ataxia and SG. The majority of patients (40%) were initially diagnosed with cerebellar dysfunction
and 30% were initially diagnosed with SG. For 30% the two diagnoses were made at the same time. The
mean latency between the two diagnoses was 6.5 ± 8.9 years (range 0–44). The commonest initial manifestation was
unsteadiness (77.5%) followed by patchy sensory loss (17.5%) and peripheral neuropathic pain (5%).
Nineteen patients (47.5%) had gluten sensitivity, of whom 3 patients (7.5%) had biopsy proven coeliac disease. Other
abnormal immunological tests were present in another 15 patients. Six patients had malignancy, which was diagnosed
within 5 years of the neurological symptoms. Only 3 patients (7.5%) were classified as having a truly idiopathic
combination of cerebellar ataxia with SG.
Conclusion: Our case series highlights that amongst patients with the unusual combination of cerebellar ataxia and
SG, immune pathogenesis plays a significant role.
Keywords: Ganglionopathy, Cerebellar ataxia, Gluten, Autoimmunity
Introduction
Ataxia is a term used to describe unsteadiness and poor
co-ordination of movements. It can occur secondary to
cerebellar dysfunction (cerebellar ataxia) or because of
dysfunction within the peripheral or central sensory
pathways (sensory ataxia).
Cerebellar ataxia can be inherited (e.g. Friedreich’s
ataxia and spinocerenellar ataxias, known as SCAs) or
acquired (e.g. gluten ataxia and paraneoplastic) [1].
Sensory ataxia is commonly seen in neuropathies
that involve sensory fibers and are more prominent in
pure sensory neuropathies involving the dorsal root
ganglia, commonly referred to as sensory gangliono-
pathies (SG) [2]. Causes of SG can be inherited (e.g.
mitochondrial disorders) or acquired (e.g. paraneo-
plastic) [3–5].
Cerebellar ataxia combined with SG is a relatively
rare neurological combination, which can sometimes
be seen in the context of hereditary ataxias [2] (e.g.
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Friedreich’s ataxia and SCA4, mitochondrial disease
and Cerebellar ataxia, neuropathy and vestibular
areflexia syndrome (CANVAS) [6]) or as a result of
exposure to toxins (e.g. amiodarone [7]).
We present a case series of patients with this unusual
combination, in an attempt to shed light into possible
underlying aetiology.
Methods
Standard protocol approvals, registrations, and patient
consents
This is a retrospective observational case series of
patients regularly attending the Ataxia clinic based at
the Royal Hallamshire Hospital (Sheffield, UK). The
South Yorkshire Research Ethics Committee has con-
firmed that no ethical approval is indicated given that all
investigations were clinically indicated and did not form
part of a research study.
Patient selection
All recruited patients had clinical and neuroimaging
evidence of progressive cerebellar dysfunction as well as
clinical and neurophysiological evidence of SG.
Neurophysiological assessments
All patients underwent detailed nerve conduction studies
including median (sensory and motor), ulnar (sensory and
motor), superficial radial (sensory), sural (sensory), super-
ficial peroneal (sensory) and tibial (motor). All sensory
nerve conduction studies were performed bilaterally. On
all occasions supramaximal stimulation of the nerves was
performed.
The diagnosis of SG was based on the established
diagnostic criteria [8, 9]. Clinically patients that pre-
sented with signs and symptoms of patchy sensory
symptoms and reduced or absent tendon reflexes
underwent nerve conduction studies. SG was con-
firmed electrophysiologically with complete absence
of sensory nerve action potentials (SNAPs) or asym-
metrical sensory fiber involvement (asymmetrical
SNAPs) with no motor involvement.
Neuroimaging assessments
All patients underwent a magnetic resonance imaging
(MRI) of the brain and a magnetic resonance
spectroscopy (MRS) of the cerebellum. The latter
technique is validated and is used to determine the
presence of cerebellar dysfunction, even in the
absence of cerebellar atrophy [10]. We measured the
N-acetyl-aspartate/creatine (NAA/Cr) ratios in the
vermis and the cerebellar hemispheres. Only patients
with cerebellar atrophy and/or abnormal NAA/Cr ra-
tios in either the vermis or the hemispheres and/or
cerebellar atrophy in the MRI where considered as
having cerebellar dysfunction.
Serologic testing
Serological testing was performed and included exten-
sive testing for possible acquired causes of cerebellar
ataxia and sensory ganglionopathy. Human leukocyte
antigen (HLA) typing was performed by the regional
blood-transfusion service.
Genetic testing
Patients with early onset cerebellar ataxia and/or family
history of ataxia were tested genetically for possible gen-
etic causes. A muscle biopsy was done in patients with a
suspected mitochondrial disease. By default we did not
include in this case series patients with Friedreich’s
ataxia (FA) as this is a well known cause of this combin-
ation of neurological deficits.
Enteropathy
Patients with gluten sensitivity underwent gastroscopy
and duodenal biopsy to establish the presence of
enteropathy. All biopsies were histologically assessed
for evidence of enteropathy (triad of villous atrophy,
crypt hyperplasia, and increase in intraepithelial
lymphocytes).
Statistical analysis
A database was developed using the statistical software
package SPSS (version 23.0 for Macintosh). Descriptive
statistics were examined for each variable.
Results
Clinical characteristics
We identified 40 patients (45% males) with combined
cerebellar ataxia and sensory ganglionopathy. Mean age
at onset of the symptoms was 53.7 ± 14.7 years (range
8–80) and mean age at first presentation was 56.6 ±
13.5 years (range 14–81). At presentation, the majority
of patients (40%) were diagnosed with cerebellar ataxia
and 30% were diagnosed with SG. For 30% the two diag-
noses were made at the same time. The mean latency
between the two diagnoses was 6.5 ± 8.9 years (range 0–
44). The commonest initial manifestation was unsteadi-
ness (77.5%) followed by patchy sensory loss (17.5%) and
peripheral neuropathic pain (5%).
Neurophysiology
Sixteen patients (40%) had absent SNAPs, whereas the
rest had asymmetrical SNAPs. No patients had abnormal
compound muscle action potentials (CMAPs). Table 1
summarizes the neurophysiological characteristics of a
typical patient with asymmetrical SNAPs (Patient 1) and
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of a patient with completely absent SNAPs (Patient 2)
from these series.
Neuroimaging characteristics
All patients had abnormal MRS at diagnosis. Fifteen
patients (37.5%) had low NAA/Cr ratio only in the
vermis (<0.96) and 6 patients (15%) had low NAA/Cr
ratio only in the hemispheres (<1). Nineteen patients
(47.5%) had low NAA/Cr ratio in both the vermis
and the hemispheres. Only 55% of the patients had
cerebellar atrophy in the initial MRI.
Evidence of autoimmunity
Nineteen patients (47.5%) had gluten sensitivity, of
whom 3 patients (7.5%) had biopsy proven coeliac dis-
ease. Other abnormal immunological tests were present
in another 15 patients (i.e. GAD, ANA etc.), of whom 4
patients (10%) had biopsy proven Sjogren’s syndrome.
Cancer
Nine patients had a history or developed malignancy
(3 bowel, 1 melanoma, 1 light chain myeloma, 2 ova-
rian, 1 uterus and 1 of unknown primary location).
However, only in 6 patients of them the malignancy
was diagnosed within 5 years of the neurological
symptoms. Anti-Yo antibodies were found in one
patient.
Genetic causes
Nineteen patients were investigated for familial
ataxias using next generation sequencing ataxia panel
containing 42 genes. In selected patients genetic test-
ing for common mitochondrial mutations (including
POLG1) and muscle biopsies were performed. For
two of them a genetic cause was identified (one mito-
chondrial, one SCA18).
HLA type
HLA typing was performed in 34 patients. Of them, 18
patients (52.9%) had the DQ2 type, 6 patients (17.6%)
had the DQ8 type, 9 patients (26.5%) had the DQ1 type
and 1 patient (2.9%) had another HLA type.
Truly idiopathic cases
After extensive immunological and genetic screening,
only 3 patients (7.5%) were classified as having a truly
idiopathic combination of cerebellar ataxia with SG
(Table 2).
Discussion
Our case series highlights that amongst patients with
cerebellar ataxia and sensory neuronopathy, where a
genetic or a malignant cause is not identified, im-
mune pathogenesis is a likely cause. In fact out of 40
patients, only 2 were found to have a genetic cause
and only 6 patients had malignancy, which was diag-
nosed within 5 years of their symptoms. From the
remaining 32 patients the vast majority (91%) had
evidence of autoimmunity and only 3 patients (9%)
were classified as truly idiopathic.
Whether considering the cut-off of 5 years for a
neurological syndrome to be classified as paraneo-
plastic is a matter of debate [11]. This time period
has been based on reports showing that in the
majority of cases the interval between the paraneo-
plastic neurological syndrome and the diagnosis of
malignancy is less than 5 years [11]. However in our
case series, there are patients who exceed this inter-
val. The type of malignancy, however, may influence
this interval.
The HLA type has been linked to predisposition to
autoimmunity. In our case series 70.5% of patients had
the DQ2 or the DQ8 HLA subtypes, which are known
to be associated with autoimmunity. This percentage is
significantly higher compared to the 40% of the general
population [12]. In addition, in our cohort, evidence for
autoimmunity (serological evidence of gluten sensitivity
and/or positive other antibody titers) was present in 90%
of the patients.
Our findings should be interpreted with some cau-
tion given the limitations of our design. Firstly, as this
is a retrospective observational case series of patients
regularly attending our Ataxia clinic not all patient’s
had full genetic screening, which means that the
percentage of genetic causes might be higher than the
one we reported. However, the bias is probably mini-
mized by the fact that we genetically tested patients
with early onset and/or family history of ataxia and
SG. When clinically suspected, patients also under-
went genetic testing for mitochondrial diseases in-
cluding muscle biopsies. Despite this it is possible
that in some patients mitochondrial aetiology [13, 14]
may have been missed. Secondly, we haven’t routinely
been examining for the vestibulo-ocular reflex and
therefore cases of CANVAS may have been missed.
However, our understanding is that most cases with
CANVAS, unlike the series here, tend to have a
family history.
Both cerebellar ataxia (gluten ataxia) and sensory
ganglionopathy in isolation have been previously
linked to gluten sensitivity [4, 10, 15]. Almost half of
the patients in this report (47.5%) had serological evi-
dence of gluten sensitivity without enteropathy
(coeliac disease). Gluten free diet has already been
shown to be beneficial in such patients [4] and
should be considered in all patients with cerebellar
ataxia and sensory ganglionopathy in the presence of
serological markers of sensitivity to gluten.
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